Literature DB >> 19476269

Current status and future potential of advanced technologies in radiation oncology. Part 2. State of the science by anatomic site.

Bhadrasain Vikram1, C Norman Coleman, James A Deye.   

Abstract

In December 2006, the Radiation Research Program of the Division of Cancer Treatment and Diagnosis of the National Cancer Institute hosted a workshop intended to address current issues related to advanced radiation therapy technologies, with an eye toward (1) defining the specific toxicities that have limited the success of "conventional" radiation therapy, (2) examining the evidence from phase III studies for the improvements attributed to the advanced technologies in the treatment of several cancers commonly treated with radiation therapy, and (3) determining the opportunities and priorities for further technologic development and clinical trials. The new technologies offer substantial theoretical advantage in radiation dose distributions that, if realized in clinical practice, may help many cancer patients live longer and/or better. The precision of the advanced technologies may allow us to reduce the volume of normal tissue irradiated in the vicinity of the clinical target volume. Part 1 of this two-part article, which appeared in the March issue of ONCOLOGY, provided a general overview of the workshop discussion, focusing on the challenges posed by the new technologies and resources available or in development for meeting those challenges. This month, part 2 will outline the state of the science for each disease site.

Entities:  

Mesh:

Year:  2009        PMID: 19476269

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  7 in total

1.  NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Authors:  Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker
Journal:  J Natl Cancer Inst       Date:  2012-12-10       Impact factor: 13.506

Review 2.  The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment.

Authors:  Ronan Lordan; Alexandros Tsoupras; Ioannis Zabetakis
Journal:  Adv Nutr       Date:  2019-01-01       Impact factor: 8.701

3.  Predictive Radiation Oncology - A New NCI-DOE Scientific Space and Community.

Authors:  Jeffrey C Buchsbaum; David A Jaffray; Demba Ba; Lynn L Borkon; Christine Chalk; Caroline Chung; Matthew A Coleman; C Norman Coleman; Maximilian Diehn; Kelvin K Droegemeier; Heiko Enderling; Michael G Espey; Emily J Greenspan; Christopher M Hartshorn; Thuc Hoang; H Timothy Hsiao; Cynthia Keppel; Nathan W Moore; Fred Prior; Eric A Stahlberg; Georgia Tourassi; Karen E Willcox
Journal:  Radiat Res       Date:  2022-04-01       Impact factor: 3.372

4.  Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical Translation.

Authors:  Pataje G S Prasanna; Deepa Narayanan; Kory Hallett; Eric J Bernhard; Mansoor M Ahmed; Gregory Evans; Bhadrasain Vikram; Michael Weingarten; C Norman Coleman
Journal:  Radiat Res       Date:  2015-08-18       Impact factor: 2.841

Review 5.  The future of Radiation Oncology: Considerations of Young Medical Doctor.

Authors:  Bartosz Urbański
Journal:  Rep Pract Oncol Radiother       Date:  2012-10-04

6.  International Conference on Advances in Radiation Oncology (ICARO): outcomes of an IAEA meeting.

Authors:  Eeva K Salminen; Krystyna Kiel; Geoffrey S Ibbott; Michael C Joiner; Eduardo Rosenblatt; Eduardo Zubizarreta; Jan Wondergem; Ahmed Meghzifene
Journal:  Radiat Oncol       Date:  2011-02-04       Impact factor: 3.481

Review 7.  Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't!

Authors:  Kaveh Zakeri; C Norman Coleman; Bhadrasain Vikram
Journal:  Front Oncol       Date:  2018-04-30       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.